Avience Biomedicals Key Ratios
NSE: AVIENCE
₹262.40
₹12.45
(4.98%)
As on 11-Nov-2026IST
Market cap
₹144 Cr
Revenue (TTM)
₹53 Cr
P/E Ratio
16.4
P/B Ratio
4.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 22.24 | 47.88 | -- |
| EBIT | -- | -- | 47.02 | 102.06 | -- |
| Net Profit | -- | -- | 34.61 | 111.89 | -- |
| EPS | -- | -- | 34.61 | 97.90 | -- |
| Book Value | -- | -- | 33.00 | 75.80 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-26 | Mar-25 | Mar-24 |
| EBIT-Margin
| -- | -- | 26.42 | 23.32 | 14.55 |
| Net Margin
| -- | -- | 16.58 | 15.46 | 8.78 |
| Return on equity
| -- | -- | 32.37 | 49.18 | 34.47 |
| Return on Capital
| -- | -- | 26.93 | 33.93 | 18.25 |
| Return on Assets
| -- | -- | 13.35 | 15.59 | 6.20 |
| Debt to Equity (x)
| -- | -- | 0.92 | 0.98 | 2.44 |
Profitability
ROCE
26.93
Higher than Peers by 14.58
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
26.93
|
33.93
|
18.25
|
--
|
--
|
|
Peer Median
|
12.36
|
13.23
|
16.51
|
17.42
|
--
|
ROE
32.37
Higher than Peers by 25.06
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
32.37
|
49.18
|
34.47
|
--
|
--
|
|
Peer Median
|
7.32
|
14.03
|
12.58
|
14.29
|
--
|
ROA
13.35
Higher than Peers by 9.43
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
13.35
|
15.59
|
6.20
|
--
|
--
|
|
Peer Median
|
3.92
|
6.05
|
6.27
|
11.08
|
--
|
EBIT Margin
26.42
Higher than Peers by 13.76
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
26.42
|
23.32
|
14.55
|
--
|
--
|
|
Peer Median
|
12.66
|
11.92
|
17.72
|
10.64
|
--
|
Net Margin
16.58
Higher than Peers by 9.78
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
16.58
|
15.46
|
8.78
|
--
|
--
|
|
Peer Median
|
6.80
|
6.31
|
8.62
|
8.68
|
--
|
Cash Profit Margin
19.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
19.00
|
17.64
|
11.51
|
--
|
--
|
|
Peer Median
|
--
|
--
|
0.00
|
0.00
|
--
|
Revenue Growth
16.07
Lower than Peers by 26.41
Year on year growth in net sales
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
16.07
|
88.77
|
--
|
--
|
--
|
|
Peer Median
|
42.49
|
19.29
|
35.34
|
69.01
|
--
|
EBIT Growth
31.49
Lower than Peers by 236.88
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
31.49
|
202.55
|
--
|
--
|
--
|
|
Peer Median
|
268.37
|
21.41
|
45.38
|
4,139.53
|
--
|
Net Profit Growth
23.30
Higher than Peers by 7.34
Year on year growth in profit after tax
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
23.30
|
231.56
|
--
|
--
|
--
|
|
Peer Median
|
15.95
|
147.16
|
65.85
|
686.54
|
--
|
EPS Growth
23.30
Higher than Peers by 1.78
Year on year growth in earnings per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
23.30
|
170.14
|
--
|
--
|
--
|
|
Peer Median
|
21.52
|
147.16
|
--
|
--
|
--
|
Book Value Growth
38.63
--
Year on year growth in book value per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
38.63
|
264.84
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.92
Higher than Peers by 0.37
Total debt / Net worth
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
0.92
|
0.98
|
2.44
|
--
|
--
|
|
Peer Median
|
0.55
|
0.32
|
0.48
|
0.12
|
--
|
Short term debt to equity ratio
0.45
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
0.45
|
0.51
|
1.12
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.46
Lower than Peers by 0.52
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
1.46
|
1.57
|
1.11
|
--
|
--
|
|
Peer Median
|
1.98
|
2.55
|
1.90
|
1.53
|
--
|
Quick Ratio
0.88
Lower than Peers by 2.37
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
0.88
|
1.02
|
0.51
|
--
|
--
|
|
Peer Median
|
3.25
|
12.10
|
1.77
|
2.22
|
--
|
Interest Coverage
8.35
Higher than Peers by 4.49
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
8.35
|
7.72
|
4.10
|
--
|
--
|
|
Peer Median
|
3.86
|
4.04
|
4.81
|
6.93
|
--
|
Operating Efficiency
Debtors to sales
40.03
Higher than Peers by 3.29
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
40.03
|
38.05
|
33.76
|
--
|
--
|
|
Peer Median
|
36.74
|
24.00
|
33.89
|
21.39
|
--
|
Asset Turnover
0.80
Lower than Peers by 0.18
Sales / Average Total Assets
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
0.80
|
0.99
|
0.69
|
--
|
--
|
|
Peer Median
|
0.98
|
0.94
|
1.29
|
0.86
|
--
|
Receivable days
132.87
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
132.87
|
102.08
|
123.23
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
105.13
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
105.13
|
102.74
|
188.80
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
105.98
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
105.98
|
86.43
|
129.93
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
132.02
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
132.02
|
118.39
|
182.09
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
53.56
|
20.16
|
51.65
|
61.00
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.33
|
2.28
|
3.04
|
6.15
|
--
|
EV/EBITDA
1.95
Lower than Peers by 17.91
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
1.95
|
1.76
|
4.00
|
--
|
--
|
|
Peer Median
|
19.87
|
14.45
|
25.55
|
11.25
|
--
|
Market Cap
--
--
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Avience Biomedicals
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
269
|
252
|
126
|
36
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
